Overview

* Orthofix Medical Q2 2025 net sales rise 2.3%, beating analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 2025 beats consensus, reflecting operational improvements

* Co launched TrueLok Elevate TBT System and Reef L Interbody System

Outlook

* Orthofix reaffirms full-year 2025 net sales guidance of $808 mln to $816 mln

* Company expects 2025 adjusted EBITDA between $82 mln and $86 mln

* Orthofix anticipates positive free cash flow for full-year 2025

Result Drivers

* U.S. SPINE FIXATION - Net sales grew 5% with procedure volume up 7%, driving revenue growth

* BONE GROWTH THERAPIES - Achieved 6% net sales growth, with a 7% increase in Fracture sales

* NEW PRODUCT LAUNCHES - Global launch of TrueLok Elevate TBT System and U.S. launch of Reef L Interbody System contributed to sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $203.10 $196.90

mln mln (5

Analysts

)

Q2 Beat $20.60 $17.80

Adjusted mln mln (5

EBITDA Analysts

)

Q2 Gross 68.7%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Orthofix Medical Inc ( OFIX ) is $22.00, about 50.7% above its August 4 closing price of $10.85

* The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 53 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)